Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors

Blood

Volumn 96, Issue 6, 2000, Pages 2062-2068

  Nash, R A ^a   Antin, J H ^a   Karanes, C ^a   Fay, J W ^a   Avalos, B R ^a   Yeager, A M ^a   Przepiorka, D ^a   Davies, S ^a   Petersen, F B ^a   Bartels, P ^a   Buell, D ^a   Fitzsimmons, W ^a   Anasetti, C ^a   Storb, R ^a   Ratanatharathorn, V ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOSPORIN; GLUCOCORTICOID; HLA ANTIGEN; IMMUNOGLOBULIN G; MACROLIDE; METHOTREXATE; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; INCIDENCE; INFECTION; KIDNEY DISEASE; LEUKEMIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MALE; METHOTREXATE; MIDDLE AGED; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0034665674     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Marrow transplantation for severe aplastic anemia: Methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease
2. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia
3. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
4. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia
5. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia
6. Marrow transplants from unrelated donors for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
7. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies
8. Effect of HLA incompatibility in marrow transplantation from unrelated and HLA-mismatched related donors
9. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation
10. A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow Transplantation (EBMT): Chronic Leukaemia Working Party of the EBMT
11. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
12. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A
13. The T-cell transcription factor NFATp is a substrate for calcineurin and interacts with Fos and Jun
14. FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin
15. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes
16. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation
17. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
18. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group
19. Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506
20. FK506 and methotrexate prevent graft-versus-host disease in dogs given 9.2 Gy total body irradiation and marrow grafts from unrelated DLA-nonidentical donors
21. Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: A single-center study
22. FK506 (tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation
23. FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow trans plantation from matched unrelated donors
24. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation
25. Phase 3 study comparing methotrexate and tacrolimus (Prograf, FK506) with methotrexate and cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation
26. Sample size requirements for evaluating a conservative therapy
27. Analysis of 462 transplantations from unrelated donors facilitated by The National Marrow Donor Program
28. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: Initial experience of the National Marrow Donor Program
29. Allogeneic bone marrow transplantation using unrelated donors: A pilot study of the Canadian Bone Marrow Transplant Group
30. Clinical bone marrow transplantation: Donor selection and recipient monitoring
31. Histocompatibility
32. Ten HLA-DR4 alleles defined by sequence polymorphisms within the DRB1 first domain
33. A whole blood FK 506 assay for the IMx analyzer
34. Progress report of an external quality assessment scheme for cyclosporine assay
35. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
36. Bone-marrow transplantation
37. Consensus conference on acute GVHD grading
38. Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression
39. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia
40. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: Major prognostic impact of HLA class I identity between donor and recipient [review]
41. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia
42. HLA-identical marrow transplantation during accelerated phase chronic myelogenous leukemia: Analysis of survival and remission duration
43. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial
44. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease
45. Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: Long-term follow-up of a controlled trial
46. Long-term cyclosporin therapy may decrease the risk of chronic graft-versus-host disease
47. Cyclosporin A and chronic graft versus host disease
48. Chronic graft-versus-host disease and other late complications of bone marrow transplantation
49. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation
50. Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation
51. Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation
52. Tacrolimus vs. cyclosporine immunosuppression: Results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine
53. Expectation bias in rheumatoid arthritis clinical trials: The anti-CD4 monoclonal antibody experience
54. Methods for assessment of graft-versus-host disease
55. IBMTR Severity Index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade
56. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate